Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Operating Income: 2023-2025

Historic Operating Income for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$52.6 million.

  • Zenas BioPharma's Operating Income fell 28.29% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$200.7 million, marking a year-over-year decrease of 50.85%. This contributed to the annual value of -$163.9 million for FY2024, which is 341.19% down from last year.
  • Latest data reveals that Zenas BioPharma reported Operating Income of -$52.6 million as of Q3 2025, which was up 4.68% from -$55.2 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Operating Income high stood at $35.6 million for Q3 2023, and its period low was -$55.6 million during Q4 2024.
  • Moreover, its 3-year median value for Operating Income was -$39.7 million (2024), whereas its average is -$33.1 million.
  • Data for Zenas BioPharma's Operating Income shows a maximum YoY crashed of 215.05% (in 2024) over the last 5 years.
  • Zenas BioPharma's Operating Income (Quarterly) stood at -$24.8 million in 2023, then plummeted by 124.48% to -$55.6 million in 2024, then fell by 28.29% to -$52.6 million in 2025.
  • Its Operating Income stands at -$52.6 million for Q3 2025, versus -$55.2 million for Q2 2025 and -$37.3 million for Q1 2025.